Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Nature Medicine
Forde, Patrick M PM; Anagnostou, Valsamo V; Sun, Zhuoxin Z; Dahlberg, Suzanne E SE; Kindler, Hedy L HL; Niknafs, Noushin N; Purcell, Thomas T; Santana-Davila, Rafael R; Dudek, Arkadiusz Z AZ; Borghaei, Hossein H; Lanis, Mara M; Belcaid, Zineb Z; Smith, Kellie N KN; Balan, Archana A; White, James R JR; Cherry, Christopher C; Ashok Sivakumar, I K IK; Shao, Xiaoshan M XM; Chan, Hok Yee HY; Singh, Dipika D; Thapa, Sampriti S; Illei, Peter B PB; Pardoll, Drew M DM; Karchin, Rachel R; Velculescu, Victor E VE; Brahmer, Julie R JR; Ramalingam, Suresh S SS